Sustained Release Excipients Market Size was valued at USD 1.4 Billion in 2023. The sustained release excipients market industry is projected to grow from USD 1.5 Billion in 2024 to USD 2.5 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.00% during the forecast period (2024 - 2032). Market drivers include the rising frequency of patent expirations and the increased need for dosage forms for the pediatric and geriatric populations, which have had a significant impact on the sustained release excipients market expansion.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The market CAGR for sustained release excipients is expected to grow in the future due to the increasing incidence of both acute and chronic diseases. Diseases are classified into two main categories based on their duration and progression - acute and chronic diseases or such prolonged periods. Acute diseases are usually characterized by rapid onset of severe but transient symptoms. The duration of these illnesses is usually short—hours, days, or weeks—and they arise suddenly. Adjuvants with long-lasting diuretics are often used to treat acute and chronic problems. These features increase sales of adjuvants that maintain consistency, even maintain dosage levels, reduce side effects, and promote patient adherence and disease management well. NCD) Most deaths—approximately 17.9 million annually—are due to cardiovascular diseases, followed by chronic respiratory diseases (4.1 million), diabetes (2 million, including diabetic kidney disease), and cancer (9.3 million) by October 2022. U.S.-based A statement by the Pan American Health Organization, an international public health organization, documented that 10.6 million individuals will be infected with tuberculosis (TB) by 2021, up 4.5% from 2020. Thus, there is a market for extracted support that has a long history of severe and chronic increases due to mounting problems.
Going forward, the market for sustained release excipients is anticipated to rise at a rapid pace due to the increasing need for personalized medication. Medical practitioners use precision medicine to deliver and plan individualized care by analyzing each patient's distinct genes, proteins, and other body parts. This approach is known as personalized medicine or personalized care. Sustained-release excipients are essential to personalized medicine because they make it possible to create medication formulations that are specific to each patient's needs. For instance, about one-third of all newly authorized therapeutic molecular entities were approved by the US Food and Drug Administration (FDA) in 2022, with 12 of those medications being personalized. Based on a paper from the US-based professional membership organization Personalized Medicine Coalition titled The Scope and Significance of Progress in 2022, this information has been compiled. Thus, the market for sustained release excipients is expanding due to the rising need for individualized treatment. Thus, driving the sustained release excipients market revenue.
The Sustained Release Excipients Market segmentation, based on product type, includes Gelatin, Polymers, Minerals, Sugars, and Others. In 2023, the polymer segment dominated the market due to their versatility and fit for a range of pharmaceutical formulations. Polymers facilitate controlled drug release by forming a matrix that regulates the release of active ingredients. Because of their versatility, they are a preferred choice for sustained-release medicine delivery systems. Furthermore, polymers are still used in pharmaceuticals since longer half-lives and longer releases are needed for medications, especially for chronic illnesses.
The Sustained Release Excipients Market segmentation, based on route of administration, includes Oral, Intramuscular, Subcutaneous, Transdermal, Intravenous, and Others. The oral category generated the most income in 2023. It is the most sensible and preferred way to provide medicine. The availability of the largest active surface area for drug absorption in comparison to alternative drug delivery technologies is a significant factor in the high share. The ease with which tablets and capsules can be produced has contributed significantly to the long-standing use of the oral route of medication delivery.
The Sustained Release Excipients Market segmentation, based on technology, includes Targeted Delivery, Microencapsulation, Wurster Technique, and Others. The targeted delivery category generated the most income in 2023. By delivering the medication to a desired location of action, targeted delivery lowers the possibility of drug toxicity by keeping the medication from entering unwanted bodily areas. Sustained release drug delivery systems achieve higher patient compliance, and localized drug distribution using targeted drug delivery technology leads to a consistent drug impact, less variation in drug levels in circulation, and a low chance of side effects.
Figure 1: Sustained Release Excipients Market, by Technology, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American sustained release excipients market area will dominate this market. Increased R&D efforts and the presence of significant pharmaceutical businesses in the area are credited with the region's success. Over the course of the forecast period, the region is expected to become more profitable due to patent expirations and the subsequent arrival of generics.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: SUSTAINED RELEASE EXCIPIENTS MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe sustained release excipients market accounts for the second-largest market share. The primary driver of market expansion is the aging population. Furthermore, it is projected that the advancement of complex biologics and the growing need for novel drug delivery systems will drive market growth in this sector. Further, the German sustained release excipients market held the largest market share, and the UK sustained release excipients market was the fastest growing market in the European region.
The Asia-Pacific Sustained Release Excipients Market is expected to grow at the fastest CAGR from 2024 to 2032. The increased incidence of numerous infectious diseases, the quickly expanding healthcare system, and the growing need for highly potent medications are all factors contributing to this region's rise. Moreover, China’s sustained release excipients market held the largest market share, and the Indian sustained release excipients market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the sustained release excipients market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the sustained release excipients industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global sustained release excipients industry to benefit clients and increase the market sector. In recent years, the sustained release excipients industry has offered some of the most significant advantages to medicine. Major players in the sustained release excipients market are attempting to increase market demand by investing in research and development operations, including Allergan PLC, AstraZeneca, GlaxoSmithKline PLC, Mayne Pharma Group Limited, Mylan NV, Novartis AG, Pfizer Inc., Salix Pharmaceuticals, and Sun Pharmaceutical Industries Ltd.
As a division of AbbVie Inc., Allergan Ltd. (Allergan) is a specialty pharmaceutical business that creates and distributes over-the-counter (OTC) and branded medications as well as biosimilars. The company sells goods in the following therapeutic categories: anti-infective, urology, women's health, dermatology, central nervous system, eye care, and gastroenterology. Its clients include mail-order merchants, hospitals, clinics, government agencies, and managed healthcare providers, including health maintenance organizations and other institutions. It also distributes its products to retailers, drug wholesalers, and distributors, including national retail medicine and grocery store chains.
Biopharmaceuticals are discovered, developed, produced, and marketed by Pfizer Inc. (Pfizer). The company offers solutions to address a variety of conditions, such as those related to women's health, cancer, inflammatory diseases, immune system issues, and metabolic, cardiovascular, and pain disorders. Additionally provided are sterile injectable drugs, biosimilars, contract manufacturing services, and active pharmaceutical ingredients (APIs). For over $6.7 billion, US-based pharmaceutical and biotechnology company Pfizer Inc. purchased Arena Pharmaceuticals in December 2021. The purchase of Arena bolsters Pfizer's capabilities and expertise in immunology and inflammation, a Pfizer innovation engine that develops effective therapies for patients with debilitating immuno-inflammatory diseases in need of new treatment options.
Key companies in the sustained release excipients market include
Sustained Release Excipients Industry Developments
June 2023: Croda, Inc. declared that work had started on a new manufacturing plant that will be located in Pennsylvania, USA. It is anticipated that this facility will boost Croda's manufacturing capacity and better meet the changing demands of the market for sustained release excipients.
September 2022: Prolanza ashwagandha (Withania somnifera) with continuous release was created by Nutriventia, a firm that specializes in facilitating connections between global suppliers and purchasers of food, health, and natural components. A modern extract made exclusively of ashwagandha roots, Prolanza is intended to offer prolonged assistance with stress relief.
February 2022: The calcitonin gene-related peptide (CGRP) receptor antagonist rimegepant has given rise to hope from Pfizer Inc., a major pharmaceutical and biotechnology firm, and Biohaven Pharmaceutical Holding startup Ltd., a clinical-stage biopharmaceutical startup. They have suggested that the 75 mg dosage of rimegepant—which comes in the form of an oral dissolving tablet—be given marketing permission.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 1.4 Billion |
| Market Size 2024 | USD 1.5 Billion |
| Market Size 2032 | USD 2.5 Billion |
| Compound Annual Growth Rate (CAGR) | 8.00% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Route of Administration, Technology, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Allergan PLC, AstraZeneca, GlaxoSmithKline PLC, Mayne Pharma Group Limited, Mylan NV, Novartis AG, Pfizer Inc., Salix Pharmaceuticals, and Sun Pharmaceutical Industries Ltd. |
| Key Market Opportunities | · Growing government initiatives, along with a rise in early intervention and prevention techniques are anticipated to drive market expansion. |
| Key Market Dynamics | · Prevalence of both acute and chronic illnesses is a key element driving market expansion in the upcoming years. · Antibiotic resistance and the increased benefits of traditional dosage forms are expected to fuel market expansion. |
Frequently Asked Questions (FAQ) :
The Sustained Release Excipients Market size was valued at USD 1.4 Billion in 2023.
The global market is projected to grow at a CAGR of 8.00% during the forecast period, 2024-2032.
North America had the largest share in the global market
The key players in the market are Allergan PLC, AstraZeneca, GlaxoSmithKline PLC, Mayne Pharma Group Limited, Mylan NV, Novartis AG, Pfizer Inc., Salix Pharmaceuticals, and Sun Pharmaceutical Industries Ltd.
The polymer category dominated the market in 2023.
The targeted delivery category had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
